(Q35002685)

5 August 2017

1 reference

title

The clinical use of somatostatin analogues in the treatment of cancer (English)

1 reference

5 August 2017

Lamberts SW

1

1 reference

5 August 2017

Krenning EP

series ordinal

2

1 reference

5 August 2017

Klijn JG

series ordinal

3

1 reference

5 August 2017

Reubi JC

series ordinal

4

1 reference

5 August 2017

publication date

1 March 1990

1 reference

Bailliere's clinical endocrinology and metabolism

5 August 2017

published in

1 reference

5 August 2017

volume

4

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

29-49

1 reference

Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Glucagonomas, VIPomas and somatostatinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

New somatostatin molecule for management of endocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Long term treatment of acromegaly with a long acting analogue of somatostatin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201-995.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Efficacy, pharmacokinetics and tolerability of a somatostatin analogue (L-363,586) in insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Visual improvement with SMS 201-995 in a patient with a thyrotropin-secreting pituitary adenoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Peptides in the Brain: The New Endocrinology of the Neuron

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Controlling the carcinoid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Carcinoid and neuroendocrine tumours of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Heterogeneity of growth hormone (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201-995, GH-releasing hormone and thyrotropin-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Stimulatory and Inhibitory Effects of Purified Hypothalamic Extracts on Growth Hormone Release from Rat Pituitaryin Vitro1

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Potential role of somatostatin analogues in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Successful treatment with SMS 201-995 of Cushing's syndrome caused by ectopic adrenocorticotropin secretion from a metastatic gastrin-secreting pancreatic islet cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Hormonal control of pancreatic cancer growth

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Gut endocrinology: clinical and therapeutic impact

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Correlative study on neuro-endocrine differentiation and presence of somatostatin receptors in breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

1 reference

7 January 2021

Somatostatin (second of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

High Density of Somatostatin Receptors in Pituitary Tumors from Acromegalic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Autoradiographic mapping of somatostatin receptors in the rat central nervous system and pituitary.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Distribution of somatostatin receptors in the human brain: an autoradiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

High incidence of somatostatin receptors in human meningiomas: biochemical characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Somatostatin binding sites in human leptomeninx

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Antiproliferative effects of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

High affinity binding of [125I-Tyr11]somatostatin-14 to human small cell lung carcinoma (NCI-H69).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Biologic and immunologic activities and applications of somatostatin analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Dexamethasone effects on somatostatin receptors in pancreatic acinar AR4-2J cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2805%2980314-3

7 January 2021

10.1016/S0950-351X(05)80314-3

Identifiers

DOI

1 reference

5 August 2017

1 reference